This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Crawford, L. J.A. Articles by Irvine, A. E. Search for Related Content PubMed PubMed Citation Articles by Crawford, L. J.A. Articles by Irvine, A. E.

Comparative Selectivity and Specificity of the Proteasome Inhibitors BzLLLCOCHO, PS-341, and MG-132

¹ Haematology, Centre for Cancer Research and Cell Biology and ² Pharmacy, Queen's University Belfast; ³ Department of Haematology, Belfast City Hospital, Belfast, United Kingdom; ⁴ Pathology, Harvard Medical School; ⁵ Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; and ⁶ Division of Cellular Biochemistry, Netherlands Cancer Institute, Amsterdam, the Netherlands

Requests for reprints: Alexandra E. Irvine, Queen's University Belfast Haematology U Floor, Tower Block, Belfast City Hospital, Lisburn Rd., Belfast, BT9 7AB United Kingdom. Phone: 0044-28-9026-3718; Fax: 011-0044-28-9026-3927; E-mail: s.irvine{at}qub.ac.uk.

The 26S proteasome is a multicatalytic protease responsible for regulated intracellular protein degradation. Its function is mediated by three main catalytic activities: (a) chymotrypsin-like (CT-L), (b) trypsin-like, and (c) peptidylglutamyl peptide hydrolysing (PGPH). Proteasome inhibition is an emerging therapy for many cancers and is a novel treatment for multiple myeloma. Here, we profile the contributions of the three catalytic activities in multiple myeloma cell lines and compare the specificity and cytotoxicity of the novel proteasome inhibitor BzLLLCOCHO and inhibitors PS-341 (Velcade, bortezomib) and MG-132. Using fluorogenic substrates and an active site-directed probe specific for proteasome catalytic subunits, we show differential subunit specificity for each of the inhibitors. Addition of BzLLLCOCHO strongly inhibited all three catalytic activities, treatment with PS-341 completely inhibited CT-L and PGPH activities, and treatment with MG-132 resulted in weak inhibition of the CT-L and PGPH activities. Multiple myeloma cells were more sensitive to induction of apoptosis by PS-341 and MG-132 than BzLLLCOCHO. This study emphasizes the need for further investigation of the effects of these compounds on gene and protein expression in the cell to allow for the development of more specific and targeted inhibitors. (Cancer Res 2006; 66(12): 6379-86)

This article has been cited by other articles:

				A. Kloss, S. Meiners, A. Ludwig, and B. Dahlmann Multiple cardiac proteasome subtypes differ in their susceptibility to proteasome inhibitors Cardiovasc Res, July 31, 2009; (2009) cvp217v2. [Abstract] [Full Text] [PDF]

				K. Rezvani, Y. Teng, Y. Pan, J. A. Dani, J. Lindstrom, E. A. Garcia Gras, J. M. McIntosh, and M. De Biasi UBXD4, a UBX-Containing Protein, Regulates the Cell Surface Number and Stability of {alpha}3-Containing Nicotinic Acetylcholine Receptors J. Neurosci., May 27, 2009; 29(21): 6883 - 6896. [Abstract] [Full Text] [PDF]

				R. Oerlemans, N. E. Franke, Y. G. Assaraf, J. Cloos, I. van Zantwijk, C. R. Berkers, G. L. Scheffer, K. Debipersad, K. Vojtekova, C. Lemos, et al. Molecular basis of bortezomib resistance: proteasome subunit {beta}5 (PSMB5) gene mutation and overexpression of PSMB5 protein Blood, September 15, 2008; 112(6): 2489 - 2499. [Abstract] [Full Text] [PDF]

				M. Vales-Gomez, S. E. Chisholm, R. L. Cassady-Cain, P. Roda-Navarro, and H. T. Reyburn Selective Induction of Expression of a Ligand for the NKG2D Receptor by Proteasome Inhibitors Cancer Res., March 1, 2008; 68(5): 1546 - 1554. [Abstract] [Full Text] [PDF]

				D. Chauhan, A. Singh, M. Brahmandam, K. Podar, T. Hideshima, P. Richardson, N. Munshi, M. A. Palladino, and K. C. Anderson Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma Blood, February 1, 2008; 111(3): 1654 - 1664. [Abstract] [Full Text] [PDF]

				N. Niknejad, M. Morley, and J. Dimitroulakos Activation of the Integrated Stress Response Regulates Lovastatin-induced Apoptosis J. Biol. Chem., October 12, 2007; 282(41): 29748 - 29756. [Abstract] [Full Text] [PDF]

				J.-Y. Liou, D. Ghelani, S. Yeh, and K. K. Wu Nonsteroidal Anti-inflammatory Drugs Induce Colorectal Cancer Cell Apoptosis by Suppressing 14-3-3{varepsilon} Cancer Res., April 1, 2007; 67(7): 3185 - 3191. [Abstract] [Full Text] [PDF]